Ziping Wang

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

To compare the overall survival (OS) of patients with advanced lung adenocarcinoma in China before and after the approved use of gefitinib, and analyze clinical factors that may affect OS.

Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center.

Adjuvant chemotherapy (ACT) can reduce the risk of recurrence and improve survival after surgical resection in non‐small cell lung cancer (NSCLC) patients. We explore the optimal time from surgery to initiation of ACT in Chinese patients with stage IIIA NSCLC.

Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.

Adjuvant chemotherapy (ACT) after radical surgery is known to improve the survival of patients with non–small cell lung cancer (NSCLC). However, there are few studies reporting the impact of age on the efficacy of ACT in NSCLC patients. All patients who received postoperative ACT in the Cancer Hospital, the Chinese Academy of Medical Sciences, between 2001 and 2013 with complete records in the database of the hospital and met the inclusion criteria were enrolled in this study for analysis. The primary end point was disease‐free survival (DFS) in terms of age. Survival analysis was performed using Kaplan–Meier estimates, log‐rank tests, and Coxs proportional hazards regression analysis. Propensity score matching (PSM) was used, survival analysis and subgroup analysis of the match data were carried out. Of 1095 patients with stage IB to stage IIIA NSCLC who underwent radical resection, 865 cases who met the inclusion criteria were analyzed. Of them, 156 (18.0%) patients were 65 years old or older, and the remaining 709 (82.0%) patients were younger than 65. The DFS between the younger group and the elderly group was not significantly different neither before PSM (100.714 weeks [95% CI: 84.421, 117.007] vs. 99.571 weeks [95% CI: 82.621, 116.522]; P = 0.555) nor after PSM (104.857 weeks [95% CI: 81.495, 128.220] vs. 97.429 weeks [95% CI: 81.743, 113.114]; P = 0.328) using the Kaplan–Meier method.The results suggest that the benefit on DFS was similar regardless of age of NSCLC patients. ACT should not be withheld from elderly patients. However, these conclusions are limited by the nature of this retrospective study, and therefore prospective trials are required for further verification.

Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study): CAPTRA-Lung study

The CAPTRA‐Lung study (NCT03334864) is a prospective observational study that will capture real‐world data of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) across China. The study aims to complement the results from current therapeutic regimens to improve the standard of diagnosis and treatment, evaluate the effectiveness and safety of systemic therapy, and determine the factors influencing the outcomes and responses to treatment. From January 2018 to December 2023, eligible patients with advanced or metastatic NSCLC who are receiving treatment and participating in follow‐up at 16 institutions in China, will be enrolled. The demographic, clinical, laboratory, and treatment characteristics and responses to treatment will be recorded in a case report form and transcribed into an electronic data capture system. Overall survival, progression‐free survival, overall response rate, and incidence of adverse events will be calculated from the time of initial enrolment until progression evaluated by physicians, last contact, date of death, or analysis cutoff date, respectively. Based on the disease characteristics and treatment strategies, four sub‐cohorts will also be established. This study cohort could serve as a pool of patients with advanced or metastatic NSCLC to support further research.

Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

Many randomized clinical trials have demonstrated that epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are advantageous over standard chemotherapy, either as front‐line treatment or as further management of patients with EGFR mutation‐positive non‐small‐cell lung cancer (NSCLC). However, which subgroup of these patients could benefit more from EGFR‐TKIs needs to be further explored. In the present study, we explored the predictive factors in such cohorts of patients who received gefitinib.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version) Yuankai SHI, Yan SUN, Cuimin DING, Ziping WANG, Changli WANG, Zheng WANG, Chong BAI, Chunxue BAI, Jifeng FENG, Xiaoqing LIU, Fang LI, Yue YANG, Yongqian SHU, Milu WU, Jianxing HE, Yiping ZHANG, Shucai ZHANG, Gongyan CHEN, Honghe LUO, Rongcheng LUO, Caicun ZHOU, Yanbin ZHOU, Qingsong PANG, Hong ZHAO, Qiong ZHAO, Aiqin GU, Yang LING, Cheng HUANG, Baohui HAN, Shunchang JIAO, Hong JIAN Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, 100021 Beijing , China; Fourth Hospital of Hebei Medical University, 050000 Shijiazhuang, China; Tianjin Medical University Cancer Institute & Hospital, 300070 Tianjin, China; Shenzhen Peoples Hospital, 518020 Shenzhen, China; The Second Military Medical University Changhai Hospital, 200433 Shanghai, China; Fudan University Zhongshan Hospital, 200032 Shanghai, China; Jiangsu Cancer Hospital, 210009 Nanjing , China; The 307th Hospital of Chinese People’ s Liberation Army, 100071 Beijing , China; Chinese People’s Liberation Army General Hospital, 100853 Beijing , China; Beijing Cancer Hospital, 100142 Beijing , China; Jiangsu Province Hospital, 210029 Nanjing, China; Qinghai University Affiliated Hospital, 810000 Xining, China; The First Affiliated Hospital of Guangzhou Medical Unversity, 510000 Guangzhou, China; Zhejiang Cancer Hospital, 310022 Hangzhou, China; Beijing Chest Hospital, Capital Medical University, 101149 Beijing , China; Harbin Medical University Cancer Hospital, 150081 Harbin, China; The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China; Nanfang Medical University Nanfang Hospital, 510515 Guangzhou, China; Tongji University Affiliated Shanghai Pulmonary Hospital, 200433 Shanghai, China; The First Affiliated Hospital, Zhejiang University, 310003 Hangzhou, China; Shanghai Chest Hospital, Shanghai Jiaotong University, 200030 Shanghai, China; Changzhou Fourth People’s Hospital, 213001 Changzhou, China; Fujian Cancer Hospital, 350014 Fuzhou, China Corresponding author: Yuankai SHI, E-mail: syuankai@cicams.ac.cn DOI: 10.3779/j.issn.1009-3419.2015.07.01